Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
June 23, 2022
April 12, 2024
8e6ecd60-8eb4-40cc-a985-2dfdb04c74be
Related Documents
Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies
Guidance DocumentSeptember 26, 2024Center for Drug Evaluation and Research
Bioavailability Studies Submitted in NDAs or INDs – General Considerations
Guidance DocumentApril 15, 2022Center for Drug Evaluation and Research
Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics: Guidance for Industry
Guidance DocumentJune 14, 2024Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox